Breaking News

Treatment achieves significant reduction in HDV levels over 4 weeks
Several new drugs win agency nod
New use seen for bisphosphonates
Researcher hopes to improve on ZMapp vaccine

Recent Headlines

Researchers find tobacco-specific nitrosamines
Risk reduced by 97% in subjects 50 years of age and older
But MARIANNE trial finds Kadcyla treatment options non-inferior
Drug targets women with defective BRCA genes found by new test

FEATURED STORIES FROM P&T DECEMBER 2014

Stephen Barlas

Over the past few years, safety and effectiveness have been the issues plaguing generic pharmaceuticals. But concern has largely faded about the quality of active pharmaceutical ingredients manufactured in places such as India or China, or the bioequivalence of products such as Budeprion XL 300 mg. Now a new series of question marks hovers over generic drugs.

Maria Sorbera PharmD
Elizabeth Chung PharmD
Christopher W. Ho PharmD, BCACP

One of the major causes of antimicrobial resistance is the overutilization of antimicrobial therapy. Annually, two million people in the United States present with infections resistant to at least one antimicrobial agent of choice typically used to treat that type of infection. In treating antimicrobial-resistant infections compared with non–antimicrobial-resistant infections, it is expected that the hospital stay will be extended by 6.4 to 12.7 days, mortality will increase twofold, and costs will rise by at least $18,588 per occurrence (results reported from a Chicago hospital in 2008). This equates to approximately $20 billion per year in direct health care costs alone.

P&T TV

From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.

Interview